Literature DB >> 16640809

Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.

Primo N Lara1, David R Gandara, Ronald B Natale.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16640809     DOI： 10.3816/CLC.2006.n.019

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  7 in total

1.  Novel systemic therapies for small cell lung cancer.

Authors:  Charles M Rudin; Christine L Hann; Craig D Peacock; D Neil Watkins
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

Review 2.  High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease.

Authors:  Derek G Power; Timothy R Asmis; Laura H Tang; Karen Brown; Nancy E Kemeny
Journal:  Med Oncol       Date:  2010-09-14       Impact factor: 3.064

Review 3.  Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.

Authors:  Isuru U Amarasena; Saion Chatterjee; Julia A E Walters; Richard Wood-Baker; Kwun M Fong
Journal:  Cochrane Database Syst Rev       Date:  2015-08-02

4.  Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.

Authors:  Alberto A Chiappori; Zhong Zheng; Tingan Chen; Bhupendra Rawal; Michael J Schell; Brian P Mullaney; Gerold Bepler
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

5.  Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.

Authors:  Yujie Chen; Lingxiao Chen; Diansheng Zhong
Journal:  Thorac Cancer       Date:  2017-03-06       Impact factor: 3.500

6.  [First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer: 
A Network Meta-analysis].

Authors:  Yujie Chen; Lingxiao Chen; Diansheng Zhong; Jing Wang; Lina Peng; Xin Feng
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2016-04-20

7.  Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

Authors:  Hisashi Tanaka; Yukihiro Hasegawa; Yuka Fujita; Atsushi Nakamura; Eiki Kikuchi; Yasutaka Kawai; Toshiyuki Harada; Naomi Watanabe; Hiroshi Yokouchi; Kazuhiro Usui; Ryota Saito; Hiroshi Watanabe; Tomomi Masuda; Tatsuro Fukuhara; Keita Kudo; Ryoichi Honda; Satoshi Oizimi; Makoto Maemondo; Akira Inoue; Naoto Morikawa
Journal:  Thorac Cancer       Date:  2021-06-02       Impact factor: 3.500
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.